Michael D. Keller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael D. Keller has a total of 611 co-authors. Here are the top co-authors by number of shared publications:
- Catherine M. Bollard
Children's National Hospital and the George Washington University Washington DC USA
12 shared publications Catherine M. Bollard
Center for Cancer and Immunology Research, Children's National Hospital, and The George Washington Cancer Center, George Washington University School of Medicine
11 shared publicationsHaili Lang
Center for Cancer and Immunology Research, and Division of Biostatistics and Study Methodology, Children's National Hospital, Washington, DC, USA
11 shared publicationsPatrick J. Hanley
Center for Cancer & Immunology Research, Children’s National Hospital, Washington, USA
7 shared publications- Patrick J. Hanley
Children’s National Hospital, Washington, USA
7 shared publications - Blachy J. Davila Saldana
Division of Blood and Marrow Transplantation, Children's National Hospital, Washington, District of Columbia
5 shared publications
Latest Publications
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (46)
Single-cell profiling of the duodenum during chronic human norovirus infection
Human noroviruses are a major cause of diarrheal disease, yet their pathogenesis remains poorly defined. We performed single-cell RNA sequencing of duodenal biopsies and matched stem cell–derived enteroids from immunodeficient individuals with chronic norovirus infection. Norovirus RNA was detected primarily in enterocytes, enteroendocrine cells, and macrophages, with the highest proportion of viral RNA-positive cells observed among M2 macrophages, followed by late enterocytes. Despite this distribution, late enterocytes produced higher viral yields than differentiated M2 macrophages in vitro. Norovirus infection was associated with the up-regulation of MHC class I-related genes and IL15 in duodenal macrophages and late enterocytes, together with increased IFNG expression by CD8 T cells. Macrophages and late enterocytes up-regulated CXCL9 and CXCL10/11 , respectively, consistent with CD8 and CD4 T cell recruitment to the duodenum. These findings show that noroviruses infect and persist across multiple permissive cell types during chronic infection, resulting in marked dysregulation of innate and adaptive immune responses that may drive pathogenesis.
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (46)
Single-cell profiling of the duodenum during chronic human norovirus infection
Human noroviruses are a major cause of diarrheal disease, yet their pathogenesis remains poorly defined. We performed single-cell RNA sequencing of duodenal biopsies and matched stem cell–derived enteroids from immunodeficient individuals with chronic norovirus infection. Norovirus RNA was detected primarily in enterocytes, enteroendocrine cells, and macrophages, with the highest proportion of viral RNA-positive cells observed among M2 macrophages, followed by late enterocytes. Despite this distribution, late enterocytes produced higher viral yields than differentiated M2 macrophages in vitro. Norovirus infection was associated with the up-regulation of MHC class I-related genes and IL15 in duodenal macrophages and late enterocytes, together with increased IFNG expression by CD8 T cells. Macrophages and late enterocytes up-regulated CXCL9 and CXCL10/11 , respectively, consistent with CD8 and CD4 T cell recruitment to the duodenum. These findings show that noroviruses infect and persist across multiple permissive cell types during chronic infection, resulting in marked dysregulation of innate and adaptive immune responses that may drive pathogenesis.
- Open Access
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Open AccessNewborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- 2 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1051.e1-1051.e10
Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT
- 2 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1051.e1-1051.e10
Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT
- Open Access
- 16 April 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3)
How I Treat: Chronic granulomatous disease
Chronic granulomatous disease (CGD) is a rare inborn error of immunity with both high risk of invasive bacterial and fungal infections as well as inflammatory complications. Though diagnostic testing via the dihydrorhodamine assay is widely available, disease recognition can be challenging due to the broad range of initial clinical presentations. Preventative antimicrobial therapy is the backbone of management, while treatment of inflammatory disease remains a challenge. Definitive therapy via hematopoietic stem cell transplantation is increasingly favored for resolution of long-term disease risks, while gene therapy remains a promising but investigational treatment. Here, we present our consensus approach to diagnosis and management of CGD.
- 16 April 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3)
Open AccessHow I Treat: Chronic granulomatous disease
Chronic granulomatous disease (CGD) is a rare inborn error of immunity with both high risk of invasive bacterial and fungal infections as well as inflammatory complications. Though diagnostic testing via the dihydrorhodamine assay is widely available, disease recognition can be challenging due to the broad range of initial clinical presentations. Preventative antimicrobial therapy is the backbone of management, while treatment of inflammatory disease remains a challenge. Definitive therapy via hematopoietic stem cell transplantation is increasingly favored for resolution of long-term disease risks, while gene therapy remains a promising but investigational treatment. Here, we present our consensus approach to diagnosis and management of CGD.
- 1 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 35 (1)
Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models
The modest number of participants enrolled in phase I/II clinical trials limits the development of accurate models to predict treatment response. This is evidenced by early-phase clinical trials evaluating partially human leukocyte antigen-matched virus-specific T cells (VSTs) to treat virus infections in immunocompromised persons. In silico models for VST response are lacking due to the small number of participants enrolled in these clinical trials. Here, we developed a generative artificial intelligence approach to overcoming the small n and then trained a binary classifier to predict the likelihood of response to third-party VST therapy. We generated synthetic patient-response training data using a variational autoencoder, whose presence improves the robustness of machine learning models. The binary classification model determines patient response with high accuracy, evidenced by cross-validation using data from 3 third-party VST trials. The combined variational autoencoder and binary classifier provide a potential solution when considering patient suitability for third-party VSTs and also offer a broadly applicable framework to enhance the performance of machine learning models using small-scale clinical datasets.
- 1 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 35 (1)
Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models
The modest number of participants enrolled in phase I/II clinical trials limits the development of accurate models to predict treatment response. This is evidenced by early-phase clinical trials evaluating partially human leukocyte antigen-matched virus-specific T cells (VSTs) to treat virus infections in immunocompromised persons. In silico models for VST response are lacking due to the small number of participants enrolled in these clinical trials. Here, we developed a generative artificial intelligence approach to overcoming the small n and then trained a binary classifier to predict the likelihood of response to third-party VST therapy. We generated synthetic patient-response training data using a variational autoencoder, whose presence improves the robustness of machine learning models. The binary classification model determines patient response with high accuracy, evidenced by cross-validation using data from 3 third-party VST trials. The combined variational autoencoder and binary classifier provide a potential solution when considering patient suitability for third-party VSTs and also offer a broadly applicable framework to enhance the performance of machine learning models using small-scale clinical datasets.
- Open Access
- 23 December 2025
- Published by Springer Nature in Research Square
Massively Scalable Single-cell Multiomic Profiling of T Cell Repertoire with REFLEX
Single-cell profiling of T cell state with immune repertoire is critical for understanding heterogenous T cell phenotypes and responses to antigen, however, existing technologies struggle to generate this information at sufficient throughput to match biological complexity. We present “REFLEX”, a novel single-cell method enabling highly scalable, cost-efficient, multiomic profiling with paired-chain TCR sequencing. REFLEX utilizes in-situ reverse transcription with integrated sample multiplexing barcodes in a way that merges seamlessly with the commonly used 10x FLEX platform to allow capture of TCR sequences at unprecedented scale and depth. We profile >2 million cells from CMV-peptide-pulsed T cell expansions, capturing TCR sequences and rich multiomic information from 1.4M T cells, identifying many putative novel CMV reactive clonotypes and illustrating the scale and transformative impact on our understanding of T cell mediated adaptive immunity achievable with REFLEX.
- 23 December 2025
- Published by Springer Nature in Research Square
Open AccessMassively Scalable Single-cell Multiomic Profiling of T Cell Repertoire with REFLEX
Single-cell profiling of T cell state with immune repertoire is critical for understanding heterogenous T cell phenotypes and responses to antigen, however, existing technologies struggle to generate this information at sufficient throughput to match biological complexity. We present “REFLEX”, a novel single-cell method enabling highly scalable, cost-efficient, multiomic profiling with paired-chain TCR sequencing. REFLEX utilizes in-situ reverse transcription with integrated sample multiplexing barcodes in a way that merges seamlessly with the commonly used 10x FLEX platform to allow capture of TCR sequences at unprecedented scale and depth. We profile >2 million cells from CMV-peptide-pulsed T cell expansions, capturing TCR sequences and rich multiomic information from 1.4M T cells, identifying many putative novel CMV reactive clonotypes and illustrating the scale and transformative impact on our understanding of T cell mediated adaptive immunity achievable with REFLEX.
- Open Access
- 26 November 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (23) , 5965-5975
Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations
Adoptive transfer of virus-specific T cells (VSTs) has been used for managing viral diseases in immunocompromised patients, including those undergoing hematopoietic stem cell transplantation and solid organ transplantation. Clinical trials targeting viruses such as cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus have demonstrated effective viral control without the toxicities associated with conventional antiviral therapies. This review explores the manufacturing, feasibility, safety, and efficacy of VSTs, complemented by 2 case studies illustrating their real-world application. We examine recent advancements in VST manufacturing that broaden their accessibility and applicability to a wider range of viral infections and immunocompromised populations. Key safety considerations, including cytokine release syndrome and graft-versus-host disease, are discussed. Lastly, we assess the expanding applications of VSTs against emerging viral targets, such as COVID-19, and address current barriers to their implementation beyond the research setting.
- 26 November 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (23) , 5965-5975
Open AccessHarnessing virus-specific T cells: expanding therapeutic strategies across diverse populations
Adoptive transfer of virus-specific T cells (VSTs) has been used for managing viral diseases in immunocompromised patients, including those undergoing hematopoietic stem cell transplantation and solid organ transplantation. Clinical trials targeting viruses such as cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus have demonstrated effective viral control without the toxicities associated with conventional antiviral therapies. This review explores the manufacturing, feasibility, safety, and efficacy of VSTs, complemented by 2 case studies illustrating their real-world application. We examine recent advancements in VST manufacturing that broaden their accessibility and applicability to a wider range of viral infections and immunocompromised populations. Key safety considerations, including cytokine release syndrome and graft-versus-host disease, are discussed. Lastly, we assess the expanding applications of VSTs against emerging viral targets, such as COVID-19, and address current barriers to their implementation beyond the research setting.
- Open Access
REFLEX, a Novel Immune Profiling Assay, Combining TCR Repertoire and Multiome at Massively Scalable Single-cell Resolution to Catapult Exploration of T-cell Derived Immunity
Single-cell profiling of T cell state with immune repertoire is critical for understanding heterogenous T cell phenotypes and responses to antigen, however, existing technologies struggle to generate this information at sufficient throughput to match biological complexity. We present “REFLEX”, a novel single-cell method enabling highly scalable, cost-efficient, multiomic profiling with paired-chain TCR sequencing. REFLEX utilizes in-situ reverse transcription with integrated sample multiplexing barcodes in a way that merges seamlessly with the commonly used 10x FLEX platform to allow capture of TCR sequences at unprecedented scale and depth. We profile >2 million cells from CMV-peptide-pulsed T cell expansions, capturing TCR sequences and rich multiomic information from 1.4M T cells, identifying many putative novel CMV reactive clonotypes and illustrating the scale and transformative impact on our understanding of T cell mediated adaptive immunity achievable with REFLEX.
Open AccessREFLEX, a Novel Immune Profiling Assay, Combining TCR Repertoire and Multiome at Massively Scalable Single-cell Resolution to Catapult Exploration of T-cell Derived Immunity
Single-cell profiling of T cell state with immune repertoire is critical for understanding heterogenous T cell phenotypes and responses to antigen, however, existing technologies struggle to generate this information at sufficient throughput to match biological complexity. We present “REFLEX”, a novel single-cell method enabling highly scalable, cost-efficient, multiomic profiling with paired-chain TCR sequencing. REFLEX utilizes in-situ reverse transcription with integrated sample multiplexing barcodes in a way that merges seamlessly with the commonly used 10x FLEX platform to allow capture of TCR sequences at unprecedented scale and depth. We profile >2 million cells from CMV-peptide-pulsed T cell expansions, capturing TCR sequences and rich multiomic information from 1.4M T cells, identifying many putative novel CMV reactive clonotypes and illustrating the scale and transformative impact on our understanding of T cell mediated adaptive immunity achievable with REFLEX.
- Open Access
- 15 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4510
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study
Novel cellular therapies may enable HIV control or cure. HIV-specific T cells targeting conserved immunogenic protein regions of HIV Gag/Pol and the entirety of HIV Nef, termed HST-NEETs, eliminate HIV infected cells in vitro. Here we enroll seven participants in an open-label, single-arm phase 1 study (NCT03485963) to evaluate the safety (primary endpoint) of two autologous administrations of HST-NEET products without prescribed lymphodepletion. Adults with well-controlled HIV on anti-retroviral therapy are eligible. Six participants completed safety monitoring. No serious product-related toxicities are observed. Secondary endpoints are to assess expansion and persistence of HIV-reactive T cell clones, and changes to the HIV reservoir for each infused participant. HIV-specific T cell and HIV anti-Env antibody responses increase in two participants after infusion two. A trend towards decreasing levels of intact proviruses is observed in 2 participants. Three participants show persistence of HIV-reactive, product-associated T cell clones for ≥40 weeks post infusions. HST-NEETs infusions are well-tolerated. Future trials are needed to evaluate the efficacy of HST-NEETs in this population.
- 15 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4510
Open AccessAutologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study
Novel cellular therapies may enable HIV control or cure. HIV-specific T cells targeting conserved immunogenic protein regions of HIV Gag/Pol and the entirety of HIV Nef, termed HST-NEETs, eliminate HIV infected cells in vitro. Here we enroll seven participants in an open-label, single-arm phase 1 study (NCT03485963) to evaluate the safety (primary endpoint) of two autologous administrations of HST-NEET products without prescribed lymphodepletion. Adults with well-controlled HIV on anti-retroviral therapy are eligible. Six participants completed safety monitoring. No serious product-related toxicities are observed. Secondary endpoints are to assess expansion and persistence of HIV-reactive T cell clones, and changes to the HIV reservoir for each infused participant. HIV-specific T cell and HIV anti-Env antibody responses increase in two participants after infusion two. A trend towards decreasing levels of intact proviruses is observed in 2 participants. Three participants show persistence of HIV-reactive, product-associated T cell clones for ≥40 weeks post infusions. HST-NEETs infusions are well-tolerated. Future trials are needed to evaluate the efficacy of HST-NEETs in this population.
- Open Access
- 27 March 2025
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 45 (1) , 1-12
Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy
Purpose: The safety and tolerability of elapegademase (elapegademase-lvlr; Revcovi ® ) a PEGylated recombinant adenosine deaminase (ADA), were demonstrated in two Phase 3 clinical trials in the U.S. and Japan in patients with ADA-deficient severe combined immunodeficiency (ADA-SCID). Elapegademase replaced Adagen ® (pegademase, a PEGylated bovine ADA) in 2018. This registry study (NCT03878069) was conducted as a post-marketing requirement to bolster the limited safety and effectiveness data on elapegademase in patients with ADA-SCID and to study patients starting on enzyme replacement therapy (ERT) de novo . Methods: Patients were managed by routine clinical care and treating physicians’ judgement from September 2019 to January 2023. Primary endpoints included trough plasma ADA activity and total trough erythrocyte deoxyadenosine nucleotides (dAXP). Secondary outcomes included lymphocyte counts, hospitalizations, infections, and safety outcomes. Results: Thirty-two patients were grouped as ERT-naïve ( n = 7; infants and children with no prior ERT [EN]); pegademase-transitioning ( n = 21; from pegademase to elapegademase [PT]); and patients who had participated in the Phase 3 clinical trial ( n = 4; STP-2279-002; [STP]). The EN group maintained optimal plasma ADA activity, increased lymphocyte counts, had manageable infections, and had no mortality for up to 30 months while on elapegademase. The STP group and 66.7% of the PT group continued to maintain satisfactory levels of both ADA and dAXP with stable rates of infections and hospitalizations and stable lymphocyte counts for up to 48.6 months. Variability on all measures was seen, but overall, patients did not deteriorate while on elapegademase. Conclusion: Effectiveness of elapegademase was maintained up to 4 years of use and with no new safety concerns.
- 27 March 2025
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 45 (1) , 1-12
Open AccessMulti-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy
Purpose: The safety and tolerability of elapegademase (elapegademase-lvlr; Revcovi ® ) a PEGylated recombinant adenosine deaminase (ADA), were demonstrated in two Phase 3 clinical trials in the U.S. and Japan in patients with ADA-deficient severe combined immunodeficiency (ADA-SCID). Elapegademase replaced Adagen ® (pegademase, a PEGylated bovine ADA) in 2018. This registry study (NCT03878069) was conducted as a post-marketing requirement to bolster the limited safety and effectiveness data on elapegademase in patients with ADA-SCID and to study patients starting on enzyme replacement therapy (ERT) de novo . Methods: Patients were managed by routine clinical care and treating physicians’ judgement from September 2019 to January 2023. Primary endpoints included trough plasma ADA activity and total trough erythrocyte deoxyadenosine nucleotides (dAXP). Secondary outcomes included lymphocyte counts, hospitalizations, infections, and safety outcomes. Results: Thirty-two patients were grouped as ERT-naïve ( n = 7; infants and children with no prior ERT [EN]); pegademase-transitioning ( n = 21; from pegademase to elapegademase [PT]); and patients who had participated in the Phase 3 clinical trial ( n = 4; STP-2279-002; [STP]). The EN group maintained optimal plasma ADA activity, increased lymphocyte counts, had manageable infections, and had no mortality for up to 30 months while on elapegademase. The STP group and 66.7% of the PT group continued to maintain satisfactory levels of both ADA and dAXP with stable rates of infections and hospitalizations and stable lymphocyte counts for up to 48.6 months. Variability on all measures was seen, but overall, patients did not deteriorate while on elapegademase. Conclusion: Effectiveness of elapegademase was maintained up to 4 years of use and with no new safety concerns.